Glenmark Pharmaceuticals receives ANDA approval for generic version of Taytulla®

Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules, 1 mg/20 mcg, the generic version of Taytulla®1 Capsules, of Allergan Pharmaceuticals International Limited.

According to IQVIA™ sales data for the 12 month period ending May 2022, the Taytulla® Capsules market2 achieved annual sales of approximately $85.9 million*.

Glenmark's current portfolio consists of 177 products authorized for distribution in the U.S. marketplace and 47 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 379.90 as compared to the previous close of Rs. 376.65. The total number of shares traded during the day was 59669 in over 2216 trades.

The stock hit an intraday high of Rs. 381.30 and intraday low of 373.10. The net turnover during the day was Rs. 22510703.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 USFDA Approval ANDA Taytulla GenericVersion